Stock Analysis, Dividends, Split History

NVTA / Invitae Corp. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)716.72
Enterprise Value ($M)733.69
Book Value ($M)138.65
Book Value / Share2.01
Price / Book5.22
NCAV ($M)22.08
NCAV / Share0.32
Price / NCAV31.92
Share Statistics
Preferred Stock Shares Outstanding 3,458,823
Common Shares Outstanding 53,705,786
Common Stock Shares Outstanding 53,595,914
Scoring Models
Piotroski F-Score2.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.77
Return on Assets (ROA)-0.94
Return on Equity (ROE)-1.25
Balance Sheet (mrq) ($M)
Quick Ration/a
Current Ratio3.75
Income Statement (mra) ($M)
Test Revenue65,169,000.00
Other Sales Revenue Net3,052,000.00
Operating Income-121.28
Net Income-123.40
Earnings Per Share Basic And Diluted-2.65
Cash Flow Statement (mra) ($M)
Cash From Operations-97.98
Cash from Investing-36.95
Cash from Financing-97.98
Identifiers and Descriptors
Central Index Key (CIK)1501134

Split History

Stock splits are used by Invitae Corp. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

REPH: Recro Pharma Analysis and Research Report

10h - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

11h - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

11h - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="

Related News Stories

Should You Invest in the ARK Genomic Revolution Multi-Sector ETF (ARKG)?

2h zacks
Launched on 10/31/2014, the ARK Genomic Revolution Multi-Sector ETF (ARKG - Free Report) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Broad segment of the equity market. (10-0)

Invitae May Become The Amazon Of Genetics - And It's Happening Faster Than Expected

2018-08-14 seekingalpha
The company is set to hit over $500 million in revenue by the end of 2020 with 50% gross margins and a market cap today of $750M. (47-0)

Week 33 Breakout Forecast: Short-Term Picks To Give You An Edge

2018-08-13 seekingalpha
Publishing 2 of the 8 new Week 32 breakout stocks that are available only to subscribers with better than 10% short-term upside potential. (21-3)

Invitae: Growth Continues Unabated

2018-08-09 seekingalpha
Today, in the spotlight is genetic testing concern Invitae, an 'off the radar' small cap stock. (6-0)

Invitae's (NVTA) CEO Sean George on Q2 2018 Results - Earnings Call Transcript

2018-08-08 seekingalpha
Good afternoon. My name is Christina, and I will be your conference operator today. At this time, I would like to welcome everyone to the Invitae Second Quarter 2018 Financial Results Conference Call. [Operator Instructions] (6-0)

CUSIP: 46185L103